Young Kyoung Jang1,2, Chul Hyoung Lyoo3, Seongbeom Park1, Seung Jun Oh4, Hanna Cho3, Minyoung Oh4, Young Hoon Ryu5, Jae Yong Choi5, Gil D Rabinovici6,7, Hee Jin Kim1,2, Seung Hwan Moon8, Hyemin Jang1,2, Jin San Lee9, William J Jagust7,10, Duk L Na1,2,11, Jae Seung Kim12, Sang Won Seo13,14,15,16. 1. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Kangnam-ku, Seoul, 06351, South Korea. 2. Neuroscience Center, Samsung Medical Center, Seoul, South Korea. 3. Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. 4. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, South Korea. 5. Department of Nuclear Medicine, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, South Korea. 6. Memory and Aging Center, University of California, San Francisco, San Francisco, CA, USA. 7. Helen Wills Neuroscience Institute, University of California, Berkeley, Berkeley, CA, USA. 8. Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea. 9. Department of Neurology, Kyung Hee University Hospital, Seoul, South Korea. 10. Center of Functional Imaging, Lawrence Berkeley National Laboratory, Berkeley, CA, USA. 11. Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea. 12. Department of Nuclear Medicine, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 138-736, South Korea. jaeskim@amc.seoul.kr. 13. Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Kangnam-ku, Seoul, 06351, South Korea. sangwonseo@empal.com. 14. Neuroscience Center, Samsung Medical Center, Seoul, South Korea. sangwonseo@empal.com. 15. Department of Health Sciences and Technology, SAIHST, Sungkyunkwan University, Seoul, South Korea. sangwonseo@empal.com. 16. Department of Clinical Research Design & Evaluation, SAIHST, Sungkyunkwan University, Seoul, South Korea. sangwonseo@empal.com.
Abstract
PURPOSE: Tau accumulation is a core pathologic change in various neurodegenerative diseases including Alzheimer's disease and frontotemporal lobar degeneration-tau. Recently, tau positron emission tomography tracers such as [18F] AV-1451 and [18F] THK5351 have been developed to detect tau deposition in vivo. In the present study, we performed a head to head comparison of these two tracers in Alzheimer's disease and frontotemporal dementia cases and aimed to investigate which tracers are better suited to image tau in these disorders. METHODS: A cross-sectional study was conducted using a hospital-based sample at a tertiary referral center. We recruited eight participants (two Alzheimer's disease, four frontotemporal dementia and two normal controls) who underwent magnetic resonance image, amyloid positron emission tomography with [18F]-Florbetaben and tau positron emission tomography with both THK5351 and AV-1451. To measure regional AV1451 and THK5351 uptakes, we used the standardized uptake value ratios by dividing mean activity in target volume of interest by mean activity in the cerebellar hemispheric gray matter. RESULTS: Although THK5351 and AV-1451 uptakes were highly correlated, cortical uptake of AV-1451 was more striking in Alzheimer's disease, while cortical uptake of THK5351 was more prominent in frontotemporal dementia. THK5351 showed higher off-target binding than AV-1451 in the white matter, midbrain, thalamus, and basal ganglia. CONCLUSIONS: AV-1451 is more sensitive and specific to Alzheimer's disease type tau and shows lower off-target binding, while THK5351 may mirror non-specific neurodegeneration.
PURPOSE:Tau accumulation is a core pathologic change in various neurodegenerative diseases including Alzheimer's disease and frontotemporal lobar degeneration-tau. Recently, tau positron emission tomography tracers such as [18F] AV-1451 and [18F] THK5351 have been developed to detect tau deposition in vivo. In the present study, we performed a head to head comparison of these two tracers in Alzheimer's disease and frontotemporal dementia cases and aimed to investigate which tracers are better suited to image tau in these disorders. METHODS: A cross-sectional study was conducted using a hospital-based sample at a tertiary referral center. We recruited eight participants (two Alzheimer's disease, four frontotemporal dementia and two normal controls) who underwent magnetic resonance image, amyloid positron emission tomography with [18F]-Florbetaben and tau positron emission tomography with both THK5351 and AV-1451. To measure regional AV1451 and THK5351 uptakes, we used the standardized uptake value ratios by dividing mean activity in target volume of interest by mean activity in the cerebellar hemispheric gray matter. RESULTS: Although THK5351 and AV-1451 uptakes were highly correlated, cortical uptake of AV-1451 was more striking in Alzheimer's disease, while cortical uptake of THK5351 was more prominent in frontotemporal dementia. THK5351 showed higher off-target binding than AV-1451 in the white matter, midbrain, thalamus, and basal ganglia. CONCLUSIONS:AV-1451 is more sensitive and specific to Alzheimer's disease type tau and shows lower off-target binding, while THK5351 may mirror non-specific neurodegeneration.
Entities:
Keywords:
Alzheimer’s disease; Av-1451; Frontotemporal dementia; THK5351; Tau
Authors: Hanna Cho; Jae Yong Choi; Mi Song Hwang; You Jin Kim; Hye Mi Lee; Hye Sun Lee; Jae Hoon Lee; Young Hoon Ryu; Myung Sik Lee; Chul Hyoung Lyoo Journal: Ann Neurol Date: 2016-07-08 Impact factor: 10.422
Authors: Eric D Hostetler; Abbas M Walji; Zhizhen Zeng; Patricia Miller; Idriss Bennacef; Cristian Salinas; Brett Connolly; Liza Gantert; Hyking Haley; Marie Holahan; Mona Purcell; Kerry Riffel; Talakad G Lohith; Paul Coleman; Aileen Soriano; Aimie Ogawa; Serena Xu; Xiaoping Zhang; Elizabeth Joshi; Joseph Della Rocca; David Hesk; David J Schenk; Jeffrey L Evelhoch Journal: J Nucl Med Date: 2016-05-26 Impact factor: 10.057
Authors: Kerstin Sander; Tammaryn Lashley; Priya Gami; Thibault Gendron; Mark F Lythgoe; Jonathan D Rohrer; Jonathan M Schott; Tamas Revesz; Nick C Fox; Erik Årstad Journal: Alzheimers Dement Date: 2016-02-15 Impact factor: 21.566
Authors: L A Massey; M A Miranda; O Al-Helli; H G Parkes; J S Thornton; P-W So; M J White; L Mancini; C Strand; J Holton; A J Lees; T Revesz; T A Yousry Journal: Neuroimage Clin Date: 2016-11-17 Impact factor: 4.881
Authors: John T O'Brien; James B Rowe; W R Bevan-Jones; Thomas E Cope; P Simon Jones; Luca Passamonti; Young T Hong; Tim D Fryer; Robert Arnold; Kieren S J Allinson; Jonathan P Coles; Franklin I Aigbirhio; Karalyn Patterson Journal: J Neurol Neurosurg Psychiatry Date: 2017-09-14 Impact factor: 10.154
Authors: Jingyun Chen; Yi Li; Elizabeth Pirraglia; Nobuyuki Okamura; Henry Rusinek; Mony J de Leon Journal: Eur J Nucl Med Mol Imaging Date: 2018-04-27 Impact factor: 9.236
Authors: Hye Joo Son; Jungsu S Oh; Jee Hoon Roh; Sang Won Seo; Minyoung Oh; Sang Ju Lee; Seung Jun Oh; Jae Seung Kim Journal: Eur J Nucl Med Mol Imaging Date: 2018-08-14 Impact factor: 9.236
Authors: Matthias Brendel; Behrooz H Yousefi; Tanja Blume; Michael Herz; Carola Focke; Maximilian Deussing; Finn Peters; Simon Lindner; Barbara von Ungern-Sternberg; Alexander Drzezga; Peter Bartenstein; Christian Haass; Nobuyuki Okamura; Jochen Herms; Igor Yakushev; Axel Rominger Journal: Front Aging Neurosci Date: 2018-06-07 Impact factor: 5.750